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Abstract
Background: The biological mechanisms underlying cancer cell motility and invasiveness remain unclear, although
it has been hypothesized that they involve some type of epithelial-mesenchymal transition (EMT).
Methods: We used xenograft models of human cancer cells in immunocompromised mice, profiling the harvested
tumors separately with species-specific probes and computationally analyzing the results.
Results: Here we show that human cancer cells express in vivo a precise multi-cancer invasion-associated gene
expression signature that prominently includes many EMT markers, among them the transcription factor Slug,
fibronectin, and a-SMA. We found that human, but not mouse, cells express the signature and Slug is the only
upregulated EMT-inducing transcription factor. The signature is also present in samples from many publicly
available cancer gene expression datasets, suggesting that it is produced by the cancer cells themselves in multiple
cancer types, including nonepithelial cancers such as neuroblastoma. Furthermore, we found that the presence of
the signature in human xenografted cells was associated with a downregulation of adipocyte markers in the
mouse tissue adjacent to the invasive tumor, suggesting that the signature is triggered by contextual
microenvironmental interactions when the cancer cells encounter adipocytes, as previously reported.
Conclusions: The known, precise and consistent gene composition of this cancer mesenchymal transition
signature, particularly when combined with simultaneous analysis of the adjacent microenvironment, provides
unique opportunities for shedding light on the underlying mechanisms of cancer invasiveness as well as
identifying potential diagnostic markers and targets for metastasis-inhibiting therapeutics.
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Background
It has been hypothesized [1-3] that cancer cells become
invasive and migratory by undergoing some type of
epithelial-mesenchymal transition (EMT) reactivating
early embryogenesis programs. Each type of EMT is
assumed to be orchestrated by different unknown combi-
nations of multiple interacting transcription factors and
signaling pathways. A set of genes comprising an “EMT
core signature” was recently derived [4] after triggering
EMTs in different ways and observing the resulting
shared changes in gene expression. However, the details
of the specific types of EMT associated with cancer inva-
sion remain elusive and complicated by the difficulty of
detecting signs of EMT in human cancer cells, and the
topic remains controversial.
A multi-cancer gene expression signature involving a
large set of genes, several among them being EMT mar-
kers coordinately overexpressed only in a subset of malig-
nant samples that have exceeded a particular staging
threshold specific to each cancer type was recently identi-
fied [5]. The signature is present in numerous publicly
available datasets from multiple cancer types from all
solid tumor types that we tried, including nonepithelial
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not in leukemia. Examples of heat maps are shown for
breast [see Additional file 1], colon [see Additional file 2],
Ewing’s sarcoma [see Additional file 3], lung [see Addi-
tional file 4], ovarian [see Additional file 5], neuroblas-
toma [see Additional file 6] and leukemia [see Additional
file 7], demonstrating the remarkable co-expression of
the genes in solid tumors. Among the overexpressed
genes are the EMT inducing transcription factor Slug
(SNAI2), various collagens and proteinases, a-SMA,
fibronectin, fibroblast activation protein, and many extra-
cellular matrix glycoproteins, suggesting a fibroblastic
nature after passing through a Slug-based EMT.
The signature, however, has its own special characteris-
tics, one of which is that the strongly co-expressed genes
COL11A1, THBS2 and INHBA have a prominent presence.
Collagen COL11A1 was found to be a reliable proxy for
the signature: in each solid tumor dataset that we tried,
the list of genes whose expression is most highly corre-
lated (using measures such as mutual information [6] or
Pearson correlation) with that of COL11A1 consistently
includes the other genes of the signature at the top, with
the only exception of glioblastoma in which COL11A1 is
not as prominently co-expressed with the other genes,
though the signature is still present otherwise. Notably, E
cadherin (CDH1)i sn o td o w n r e g u l a t e da tl e a s ta tt h e
mRNA level. Furthermore, the signature contains numer-
ous other EMT associated genes. Table 1 identifies the
known EMT markers among the list of the 64 genes corre-
sponding to the 100 most overexpressed probe sets pre-
viously reported [5], of the signature. Highlighted by bold
typeface among these 64 are 20 known EMT-associated
genes, 17 coming from the list of 91 upregulated “EMT
core signature” [4] genes (COL5A2, FAP, POSTN,
COL1A2, COL3A1, FBN1, TNFAIP6, MMP2, GREM1,
BGN, CDH11, SPOCK1, DCN, COPZ2, THY1, PCOLCE,
PRRX1)p l u st h eo b v i o u sE M Tm a r k e r sSNAI2, FN1,
ACTA2. Four additional genes (underlined but not bold in
Table 1), PDGFRB, SPARC, INHBA, COL6A2,h a v ea l s o
been reported as EMT-related [7], for a total of 24 EMT
factors. Even without including these additional seven
genes, the P value of encountering 17 out of 64 genes
taken from the list of the 91 EMT core signature genes is
2×1 0
-22. Therefore, this fibroblastic signature is the
result, at least in part, of an EMT.
The initiation of significant signature overexpression
after reaching a particular cancer-type-specific stage sug-
gests an underlying biological mechanism associated with
cancer invasion. Given the heterogeneity of cells in
tumors, it could also reflect the superposition of several
mechanisms. Among other possibilities, the fibroblast-like
cells producing the signature could be derived from multi-
ple sources, such as the bone marrow, the local stroma,
or the cancer cells after undergoing a mesenchymal
transition. A fundamental question, therefore, is which
among the genes of the signature are expressed by the
cancer cells and which are expressed by the adjacent
microenvironment.
We also observed that there is a striking similarity [8]
between the set of genes in the signature and a subset of
the genes that are known to be lower expressed when
mouse embryonic fibroblasts are reprogrammed into
induced pluripotent stem cells [9]. Because it is known
[10] that a mesenchymal-epithelial transition (MET) is
part of the reprogramming of mouse fibroblasts into
stem cells, we reasoned that, conversely, the signature
may correspond to some kind of EMT-related transition
Table 1 Top genes overexpressed in the fibroblastic
signature (see text for designation with boldface and
underline)
Rank Probe set Gene Rank Probe set Gene
1 37892_at COL11A1 33 202998_s_at LOXL2
2 203083_at THBS2 34 201438_at COL6A3
3 217428_s_at COL10A1 35 209596_at MXRA5
4 221729_at COL5A2 36 213764_s_at MFAP5
5 210511_s_at INHBA 37 204589_at NUAK1
6 213909_at LRRC15 38 217762_s_at RAB31
7 212488_at COL5A1 39 201150_s_at TIMP3
8 204619_s_at VCAN 40 221541_at CRISPLD2
9 209955_s_at FAP 41 205422_s_at ITGBL1
10 202311_s_at COL1A1 42 207173_x_at CDH11
11 203878_s_at MMP11 43 213338_at TMEM158
12 210809_s_at POSTN 44 202363_at SPOCK1
13 202404_s_at COL1A2 45 204051_s_at SFRP4
14 202952_s_at ADAM12 46 202283_at SERPINF1
15 215076_s_at COL3A1 47 209335_at DCN
16 215446_s_at LOX 48 219655_at C7orf10
17 210495_x_at FN1 49 219561_at COPZ2
18 201792_at AEBP1 50 219773_at NOX4
19 212353_at SULF1 51 204464_s_at EDNRA
20 202766_s_at FBN1 52 200974_at ACTA2
21 219087_at ASPN 53 202273_at PDGFRB
22 200665_s_at SPARC 54 61734_at RCN3
23 202450_s_at CTSK 55 213139_at SNAI2
24 206026_s_at TNFAIP6 56 220988_s_at C1QTNF3
25 222020_s_at HNT 57 205713_s_at COMP
26 206439_at EPYC 58 201105_at LGALS1
27 201069_at MMP2 59 213869_x_at THY1
28 205479_s_at PLAU 60 202465_at PCOLCE
29 218469_at GREM1 61 209156_s_at COL6A2
30 201261_x_at BGN 62 221447_s_at GLT8D2
31 213125_at OLFML2B 63 204114_at NID2
32 201744_s_at LUM 64 205991_s_at PRRX1
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early embryogenesis. Therefore, we hypothesized that
many among the genes in the signature may be expressed
by cancer stem cells (CSCs) passing through some type of
EMT. Furthermore, because oft h ep r o m i n e n tp r e s e n c e
of inhibin-A (INHBA) in the signature, we hypothesized
that activin A (INHBA dimer) signaling may be responsi-
ble for the signature.
To test these two hypotheses and to identify which
among the genes of the signature, if any, are expressed by
the cancer cells, we used xenograft models implanting
human cancer cell lines into NCR nude mice. Since the sig-
nature was clearly found in neuroblastoma [see Additional
file 6], in which we already had successful experience of
xenograft experimentation, we used a neuroblastoma cell
line even though it is not strictly an epithelial tumor, as
this could shed further light on the complex biological
underlying mechanisms. Some of the implanted cancer cell
lines were in their original form, some were engineered to
express INHBA, and some were engineered to express the
activin antagonist follistatin (FST). Each of the resulting
growing tumors was harvested and profiled for gene
expression twice using human and mouse microarrays
separately. Our results validated the first hypothesis, but
not the second: Most of the genes of the signature were
found in human, but not mouse, cells, and their presence
was independent of any transfections, indicating that acti-
vin signaling does not play a causal role.
Specifically, our experiments confirmed that the genes of
the signature, Slug being prominent among them, are co-
expressed across samples to various degrees covering a
continuous range of values including some samples with
large expression of these genes. This result is consistent
with the publicly available cancer gene expression datasets.
Figure 1 shows that Slug is indeed co-expressed with the
key genes COL11A1 and THBS2 in various cancer types,
but not leukemia. The remarkable continuity of the dots
shown in the scatter plots of Figure 1A-C suggests a
dynamic and potentially reversible process as the human
cancer cells pass through a mesenchymal transition
process.
Methods
Tumor implantation
An inoculum of 106 NGP neuroblastoma cells containing
FUW-Luciferase plasmid (kindly donated by Dr. Adolfo
Ferrando) suspended in 0.1 mL of phosphate-buffered
saline (PBS) was injected into the left kidney of 18 mice.
The NGP cell line was originally obtained from Garrett
Brodeur, Children’s Hospital of Philadelphia. All cells
were authenticated by short tandem repeat profiling ana-
lysis. Some of the implanted cells had previously been
stably co-transfected with either FST-pReceiver-Lv105 or
INHBA pReceiver-Lv105 (GeneCopoeia; Rockville, MD).
Seven mice were implanted with INHBA-transfected
NGP cells, six with FST and five with control NGP cells.
All mice experiments and breeding were conducted
according to protocols approved by the Columbia Uni-
versity IACUC.
Harvesting of specimens
Mice were sacrificed when estimated tumor weight
reached 1.5 g followed by collection of contralateral kid-
ney and tumor. Tumor tissue was snap frozen for RNA
isolation.
Microarrays and probes preparation
HG-U133A 2.0 (human genome) and 430 A2.0 (mouse
genome) Gene Chips (Affymetrix, Santa Clara, CA) were
used to investigate gene expression in xenograft tumors.
The cRNA probes were synthesized as recommended by
Affymetrix, purified using RNeasy and fragmented
according to the Affymetrix protocol, and 15 μg of bioti-
nylated cRNA were hybridized to the microarrays. The
samples were scanned with Affymetrix Gene Chip Scan-
ner 3000.
RNA isolation and semiquantitative reverse
transcription-PCR
T o t a lR N Aw a si s o l a t e df r o mt u m o r su s i n gQ i a g e nm i R -
Neasy mini kit (Qiagen, Germantown, MD) followed by
reverse transcription using SuperScript First-Strand
synthesis System for RT-PCR from Invitrogen according
to manufacture recommendations (Carlsbad, CA, USA).
Relative expression of human versus mouse COL11A1
(Hs00266273_m1, Ms00483387_m1) genes in tumor
xenografts were examined by RT-PCR. Products were
detected by Hot Start-IT Probe qPCR Master Mix from
USB Affymetrix (Santa Clara, CA) according to manufac-
ture instructions and analyzed by Stratagene Mx3005p
real time PCR machine. After scanning, expression values
for genes were determined using MxPro 410 (Agilent
Technologies, Inc., Santa Clara, CA). Human HPRT,
CYC, GAPD and mouse GAPD, ACTB, GUSB expression
values were used to correct for sample variations in RT-
PCR efficiency and errors in quantitation.
Microarray dataset
The data set, corresponding to 18 tumors profiled sepa-
rately with human and mouse microarrays, has been
deposited in NCBI’s Gene Expression Omnibus (GEO)
and is available through accession number GSE34481.
Data were RMA normalized using the Bioconductor
open source software.
Differential expression analysis
We regrouped the 18 samples, according to the expres-
sion level of human COL11A1, into seven samples with
Anastassiou et al. BMC Cancer 2011, 11:529
http://www.biomedcentral.com/1471-2407/11/529
Page 3 of 9high or intermediate COL11A1 expression values, and
eleven with low COL11A1 expression values. Based on
this partition, we performed differential expression ana-
lysis using significance analysis of microarrays (SAM)
[11], implemented in the Bioconductor package samr.
We define the significantly differentially expressed gene
as those having both a Q value less than 0.05 and a
fold-change greater than 2.
Results
We found very different expression levels (Figure 2) for
most genes in human and mouse, suggesting that inter-
species hybridization is minimal, as previously reported
[12], which was confirmed with real-time PCR (see
Materials and Methods and Figure 3). Using COL11A1
as a proxy, we ranked the 18 samples accordingly and
investigated if most of the genes in Table 1 were
Figure 1 Color-coded scatter plots for the coexpression of the EMT inducing transcription factor Slug (SNAI2) The scatter plots
indicate the strong co-expression with the main signature genes COL11A1 and THBS2, as well as the continuity of the passing of
cancer cells through a Slug-based EMT in solid tumors, and the total absence of the co-expression of these genes otherwise. A, B and
C, plots from three solid tumor datasets. D, plot from a leukemia dataset.
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indeed the case in human cells only. For example,
Figures 2A-B show color-coded scatter plots in human
and mouse of the 18 samples for the expression of Slug
(SNAI2) in terms of the expression of the main genes of
the signature, COL11A1 and THBS2 (same as in the
scatter plots of Figure 1 suggesting an identical biologi-
cal process) demonstrating that this co-expression is
clearly present in the human cells, but absent in the
mouse cells. Specifically, seven samples had high or
intermediate levels of co-expressed genes in the human
cells, while the remaining 11 have relatively lower levels.
Based on this partition, we identified 398 significantly
(both Q < 0.05 and FC > 2) up-regulated genes, 29 among
which (COL11A1, THBS2, COL5A2, COL5A1, VCAN,
COL1A1, COL3A1, FN1,SULF1, FBN1, ASPN, SPARC,
CTSK, MMP2, BGN, LUM, LOXL2, COL6A3, TIMP3,
CDH11, SERPINF1, EDNRA, ACTA2, PDGFRB,S N A I 2 ,
Figure 2 Color-coded scatter plots in human and mouse of the 18 samples for Slug expression The expression of the EMT inducing
transcription factor Slug (SNAI2) is shown in terms of the expression of the main signature genes COL11A1 and THBS2. A,
demonstration that this co-expression is present in the xenografted human cells. B, demonstration that this co-expression is absent in the
peritumoral mouse cells. C, Bar diagram indicating that other EMT inducing transcription factors are not co-expressed.
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Page 5 of 9LGALS1, GLT8D2, NID2, PRRX1) belong to the set of 64
genes in Table 1 (P =1 0
-27), as well as VIM (vimentin).
T h ep r e s e n c ei nt h i sl i s to fSNAI2 (Slug), ACTA2 (a-
SMA), FN1 (fibronectin), VIM (vimentin), together with
many of the other EMT markers mentioned above, indi-
cates that some human cancer cells underwent EMT.
Other EMT-inducing transcription factors (Snail, Twist,
ZEB1, ZEB2, SIP1, FOXC2) were not upregulated (Figure
2CC), while the upregulationo fS N A I 2( F i g u r e2 A )w a s
very significant (Q <3×1 0
-4 and FC = 5.22).
The heat map in Figure 4 shows the co-expression of the
above 29 significantly upregulated genes. INHBA, the third
prominent gene of the signature in addition to COL11A1
and THBS2, is not included in the list, because its expres-
sion was manipulated by the transfections with consistent
results. Furthermore, the transfections of cancer cells with
either INHBA (labeled I) or FST (labeled F) did not have
a n ye f f e c to nt h ep r e s e n c eo ft h es i g n a t u r e( t h ec o r r e -
sponding expression levels were consistent with the trans-
fections and did not affect the expression of the other
genes in the signature).
These same 29 genes are used in the heat maps shown
in the Additional files, suggesting that the same signa-
ture may be expressed in all solid tumors, even in none-
pithelial tumors, such as neuroblastoma and Ewing’s
sarcoma. Therefore, our results imply that the underly-
ing mesenchymal transition process is more general
than what EMT is presumed to be.
We next analyzed the mouse microarray data to identify
genes correlated with the presence of the cancer EMT sig-
nature in the human cells. We found 32 significantly (both
Q < 0.05 and FC > 2) downregulated mouse genes in the
presence of the human cancer EMT signature. Among
them, the top two genes with the highest fold change (12.3
and 11.8 respectively) were the adipocyte markers adipo-
nectin (ADIPOQ)a n da d i p s i n( CFD). We observed that
these genes were strongly co-regulated with many other
adipocyte markers, including fatty acid binding protein 4
(FABP4)a k aaP2. This cluster of adipocyte markers whose
downregulation in the mouse cells is strongly associated
with the upregulation of the EMT signature genes in
human cells is also shown in the heat map of Figure 4.
Many among these genes are known as adipocyte differen-
tiation markers, and their downregulation is consistent
with the finding that adipocytes are dedifferentiated as
they encounter adjacent invading cancer cells in a “vicious
cycle” [13] of a complex interaction facilitating cancer cell
invasiveness. The observed downregulation of adipocyte
markers in the adjacent mouse tissue, associated with the
EMT-specific gene expression of the human cells provides
a potential molecular control mechanism of microenviron-
mental contextual interactions in accordance with pre-
viously published results.
In summary, we have shown that a precise multi-can-
cer EMT signature present in numerous publicly avail-
able datasets was found in our xenograft experiments
not to be expressed by the stromal cells, but instead by
the human cancer cells themselves in vivo. Prior to our
experiments, this was an open question. Indeed, similar
signatures were usually referred to as “stromal,” because
they contain genes, such as a-SMA, that are typically
found in stromal cells such as fibroblasts. Therefore,
Figure 3 Quantitative PCR Shown is the expression of human COL11A1 (A) or mouse COL11A1 (B) in RNA samples isolated from
tumor NGP xenografts (number indicated). Expression of human COL11A1 increased in samples from left to right consistent with microarray
results. Data were normalized to the expression of human HPRT. Mouse COL11A1 was not expressed in samples. Data was normalized to the
expression of mouse Actb. Graphs depicted as relative levels of human (A) or mouse (B) control reference RNA.
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EMT can convert cancer cells into mesenchymal, fibro-
blast-like cells that may well assume the duties of can-
cer-associated fibroblasts in some tumors [14]. Of
additional significance is the knowledge of the precise
composition of this particular Slug-based signature (as
found both in our xenograft experiments as well as
numerous cancer datasets) as it provides opportunities
for identifying potential targets for inhibiting the under-
lying biological mechanism of mesenchymal transition
of cancer cells.
Discussion
The quality of “stemness” in cells appears to be closely
interconnected with the ability to pass through transi-
tions to and from mesenchymal characteristics. Indeed,
EMT generates cells with properties of stem cells [15]
and, conversely, MET is involved in the reprogramming
of fibroblasts into stem cells [10]. Therefore, we specu-
late [8] that the cancer mesenchymal transition signa-
ture identified in this work may initiate from CSCs,
which may even appear spontaneously [16]. It is also
possible that the adipocytes of the stroma adjacent to
Figure 4 Heat map combining human and mouse genes. The 29 human genes include many EMT factors and were found to be significantly
co-expressed in the cancer cells.
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cell-like state and, together with other mesenchymal
stem cells derived from the bone marrow [17] interact
with the invading fibroblastic cancer cells in a manner
that reactivates a particular early embryonic develop-
mental program.
Not all genes in Table 1 are upregulated in the human
cells. For example, PLAU (urokinase plasminogen activa-
tor) is slightly upregulated only in mouse cells consis-
tently with its assumed role of being secreted by reactive
stromal cells as a pro-enzyme that activates itself and
other proteases in the presence of cancer cells.
Another prominent gene of the signature observed in
public databases that was not upregulated in the human
xenografted cells is MMP11 (matrix metallopeptidase 11,
aka stromelysin 3), in agreement with the hypothesis
[13,18,19] that MMP11 is expressed in the adipocytes of
the adjacent reactive stroma, indicating that the full ver-
sion of the cancer mesenchymal transition signature may
be stabilized by contextual microenvironmental signals
when cancer cells encounter adipocytes triggering their
dedifferentiation, apoptosis, or metabolism [13]. The
expression in cancer cells of the adipocyte enhancer bind-
ing protein 1 (AEBP1), a prominent gene of the signature
known to bind in the promoter region of the adipocyte
fatty-acid protein FABP4 may play an important role in
that respect, as may also the presence of oxidative stress
and TNF signaling suggested by the presence of TNFAIP6
and C1QTNF3 in the signature.
The hypothesis that the mesenchymal transition signa-
ture is triggered by adipocytes is consistent with the facts
[5] that in breast cancer the signature overexpression
appears immediately upon reaching invasive stage I, while
in ovarian cancer overexpression appears only when the
tumor is already well into stage III as in omental metasta-
sis, because ovarian cancer initially progresses by dissemi-
nating locally across mesothelial surfaces and probably
carried by the physiological movement of peritoneal fluid
to the peritoneum and omentum, a fatty structure [20].
T h er e m a r k a b l ec o n t i n u i t yo ft h es i g n a t u r e( F i g u r e s1
and 2) suggests that it may reflect a reversible process in
which the mesenchymal markers in the cancer cells may
appear and disappear depending on microenvironmental
contextual signals. Its potential reversal is consistent with
the possibility that passing through this mesenchymal
transition at some point is a requirement for the initial
stage of all metastases, even though the signature is signifi-
cantly observed only in a subset of high-stage extracted
samples at any given time. In other words, the lack of the
signature in a particular extracted sample does not imply
that cancer is not invasive, because the signature may have
appeared earlier. However, the presence of the signature
implies that the cancer is invasive; therefore a potential
related biomarker product would have high selectivity, but
not sensitivity.
Conclusions
Many among the genes of the signature expressed by
the human xenografted cells have previously been indi-
vidually identified as associated with metastatic potential
in cancer. Such associations can now largely be
explained by the fact that these genes are expressed by
the cancer cells themselves undergoing a mesenchymal
transition. The known precise composition of the signa-
ture, particularly when combined with its separation in
a species-specific manner in xenograft models, provides
multiple and unique opportunities for understanding the
underlying biological mechanisms and identifying diag-
nostic and prognostic markers as well as potential tar-
gets for metastasis-inhibiting therapeutics.
Additional material
Additional file 1: Heat map of breast cancer data set This file
contains the heat map of the TCGA breast cancer data set for the
genes of the mesenchymal transition signature.
Additional file 2: Heat map of colon cancer data set This file
contains the heat map of the TCGA colon cancer data set for the
genes of the mesenchymal transition signature.
Additional file 3: Heat map of Ewing’s sarcoma data set This file
contains the heat map of a Ewing’s sarcoma data set (GEO
accession number GSE12102) for the genes of the mesenchymal
transition signature.
Additional file 4: Heat map of lung cancer data set This file
contains the heat map of the TCGA lung cancer data set for the
genes of the mesenchymal transition signature.
Additional file 5: Heat map of ovarian cancer data set This file
contains the heat map of the TCGA ovarian cancer data set for the
genes of the mesenchymal transition signature.
Additional file 6: Heat map of neuroblastoma data set This file
contains the heat map of a neuroblastoma data set (GEO accession
number GSE3960) for the genes of the mesenchymal transition
signature.
Additional file 7: Heat map of leukemia data set This file contains
the heat map of the TCGA leukemia data set for the genes of the
mesenchymal transition signature.
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